Ratio Therapeutics raised $70 million to advance radiopharmaceutical trial development, funding continued work in its radiopharma pipeline. The Series C was described as coming from existing investors Duquesne Family Office and Bristol Myers Squibb alongside new backers, positioning the company for additional preclinical-to-clinic execution. At the same time, Vogenx signaled IPO plans with $67 million targeted, reflecting how radiopharma- and oncology-linked modalities continue to attract financing tied to near-term clinical milestones. For biotech investors, these moves highlight the continued willingness to fund imaging and targeted radiotherapeutics when programs have credible trial pathways and clear advancement triggers.